stoxline Quote Chart Rank Option Currency Glossary
  
Procaps Group S.A. (PROC)
1.01  0 (0%)    06-17 16:00
Open: 0.9999
High: 1.01
Volume: 652,298
  
Pre. Close: 1.01
Low: 0.9999
Market Cap: 114(M)
Technical analysis
2025-07-18 4:43:52 PM
Short term     
Mid term     
Targets 6-month :  1.69 1-year :  1.97
Resists First :  1.45 Second :  1.69
Pivot price 1.41
Supports First :  0.56 Second :  0.01
MAs MA(5) :  1.39 MA(20) :  1.33
MA(100) :  1.3 MA(250) :  1.66
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  57.9 D(3) :  78.1
RSI RSI(14): 55.5
52-week High :  3.77 Low :  0.01
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PROC ] has closed above bottom band by 34.9%. Bollinger Bands are 85.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.4 - 1.41 1.41 - 1.42
Low: 1.38 - 1.39 1.39 - 1.4
Close: 1.39 - 1.4 1.4 - 1.41
Company Description

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Headline News

Mon, 03 Feb 2025
Procaps Group Receives Delisting Notice From Nasdaq - GlobeNewswire

Fri, 03 Jan 2025
Procaps Group Faces New Nasdaq Delinquency Notice Over Missing Financial Statements - Stock Titan

Fri, 20 Dec 2024
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates - GlobeNewswire

Tue, 03 Dec 2024
Procaps Group Announces Financing, Shareholders Agreement and Board Updates - GlobeNewswire

Thu, 10 Oct 2024
Procaps Issues Shareholder Letter Update - Yahoo Finance

Fri, 28 Jun 2024
Procaps Group Announces New Chairman - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 113 (M)
Shares Float 17 (M)
Held by Insiders 83 (%)
Held by Institutions 2.9 (%)
Shares Short 114 (K)
Shares Short P.Month 163 (K)
Stock Financials
EPS 0.66
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.38
Profit Margin 12.6 %
Operating Margin 11.1 %
Return on Assets (ttm) 6.2 %
Return on Equity (ttm) 373.7 %
Qtrly Rev. Growth 7.3 %
Gross Profit (p.s.) 2.02
Sales Per Share 3.67
EBITDA (p.s.) 0.5
Qtrly Earnings Growth -63.8 %
Operating Cash Flow 63 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio 2.12
PEG Ratio 0
Price to Book value 3.58
Price to Sales 0.38
Price to Cash Flow 2.5
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android